A Modified NHL-BFM-95 Regimen Produces Better Outcome ThanHyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma,a Two-Institution Experience
- Author:
Chun LI
1
;
Zhi-Jun WUXIAO
;
Xiaoqin CHEN
;
Guanjun CHEN
;
Yue LU
;
Zhongjun XIA
;
Yang LIANG
;
Hua WANG
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2020;52(2):573-585
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Lymphoblastic lymphoma (LBL) is an invasive neoplasm of precursor T-cell or B-cell lineage.A broadly accepted standard treatment for adult LBL has not yet been defined.
Materials and Methods:To address this issue, we compared two chemotherapy regimens: a modified non-Hodgkinlymphoma Berlin–Frankfurt–Mu!nster-95 (NHL-BFM-95) regimen and HyperCVAD/MA. Thisretrospective study consecutively enrolled 207 adult LBL patients at two hospitals from2000 to 2018. Univariate and multivariate analysis were used to assess prognostic factors.
Results:In the present study, most clinical characteristics were similar between the two treatmentgroups except for age and lactate dehydrogenase (LDH) level. Patients treated with modifiedNHL-BFM-95 regimen tended to be younger and with elevated LDH level. The modified NHLBFM-95 regimen produced better treatment outcomes than those with HyperCVAD/MA inpatients with T-LBL or patients < 40 years. Treatment with HyperCVAD/MA, high EasternCooperative Oncology Group scores, and bone marrow involvement were independent riskfactors in T-LBL. No patients interrupted treatment for severe adverse events.
Conclusion:The results suggested that the modified regimen is well-tolerated and can produce the promisingoutcomes in patients with T-LBL or patients < 40 years.
